ArticleCardiovascular diabetology2024

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Phyo T Htoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.